<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225352</url>
  </required_header>
  <id_info>
    <org_study_id>19220</org_study_id>
    <secondary_id>2016-004546-29</secondary_id>
    <nct_id>NCT03225352</nct_id>
  </id_info>
  <brief_title>A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets</brief_title>
  <official_title>An Open Label, Randomized, Four-Way Crossover Trial to Assess the Disintegration, Gastric Emptying and Pharmacokinetic Parameters of a New Disintegrating Acetylsalicylic Acid 500 mg, 1000 mg Tablet Formulation and 2 Different Ibuprofen Tablets in Fasted Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Actual">October 16, 2017</completion_date>
  <primary_completion_date type="Actual">October 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete tablet disintegration</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>The tablet is radiolabeled. Scintigraphy images of the abdominal area will be taken It is time until an image with no definable hot spot remaining is identified</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric empty time, if applicable</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Gastric emptying time will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of colon arrival, if applicable</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Time of colon arrival will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small intestine transit time, if applicable</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Small intestine transit time will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of onset of release of radiolabel</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Time of onset of release of radiolabel will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of onset of release of radiolabel</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Site of onset of release of radiolabel will be determined by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of completion of release of radiolabel</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Site of completion of release of radiolabel will be determined by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disintegration rate of the tablet estimated from the radioactivity remaining</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Disintegration rate of the tablet estimated from the radioactivity rem will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of 50% disintegration of the tablet estimated from the radioactivity remaining</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Time of 50% disintegration of the tablet estimated from the radioactivity remaining will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying kinetics of dispersed radioactive material (t50% and t90%)</measure>
    <time_frame>Up to 4 hours</time_frame>
    <description>Gastric emptying kinetics of dispersed radioactive material (t50% and t90%) will be calculated by a qualified assessor based on the scintigraphy images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to the last data point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
    <description>Maximum drug concentration in plasma after single dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
    <description>Half-life associated with the terminal slope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
    <description>Time to reach maximum drug concentration in the measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/AUC0-infinity</measure>
    <time_frame>Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Moderate Pain</condition>
  <arm_group>
    <arm_group_label>Sequence 1: starting with BAYE4465 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: starting with BAYE4465 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3: starting with Nurofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4: starting with Dolormin Extra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg acetylsalicylic acid (Aspirin, BAYE4465)</intervention_name>
    <description>Single intake of 1 tablet, 500mg</description>
    <arm_group_label>Sequence 1: starting with BAYE4465 500 mg</arm_group_label>
    <arm_group_label>Sequence 2: starting with BAYE4465 1000 mg</arm_group_label>
    <arm_group_label>Sequence 3: starting with Nurofen</arm_group_label>
    <arm_group_label>Sequence 4: starting with Dolormin Extra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000 mg acetylsalicylic acid (Aspirin, BAYE4465)</intervention_name>
    <description>Single intake of 1 tablet, 1000mg</description>
    <arm_group_label>Sequence 1: starting with BAYE4465 500 mg</arm_group_label>
    <arm_group_label>Sequence 2: starting with BAYE4465 1000 mg</arm_group_label>
    <arm_group_label>Sequence 3: starting with Nurofen</arm_group_label>
    <arm_group_label>Sequence 4: starting with Dolormin Extra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg ibuprofen(Nurofen)</intervention_name>
    <description>Single intake of 1 tablet, 400mg</description>
    <arm_group_label>Sequence 1: starting with BAYE4465 500 mg</arm_group_label>
    <arm_group_label>Sequence 2: starting with BAYE4465 1000 mg</arm_group_label>
    <arm_group_label>Sequence 3: starting with Nurofen</arm_group_label>
    <arm_group_label>Sequence 4: starting with Dolormin Extra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg ibuprofen (Dolormin Extra)</intervention_name>
    <description>Single intake of 1 tablet, 400mg</description>
    <arm_group_label>Sequence 1: starting with BAYE4465 500 mg</arm_group_label>
    <arm_group_label>Sequence 2: starting with BAYE4465 1000 mg</arm_group_label>
    <arm_group_label>Sequence 3: starting with Nurofen</arm_group_label>
    <arm_group_label>Sequence 4: starting with Dolormin Extra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18 to 65 years included

          -  Verified diagnosis of &quot;healthy&quot;

          -  Non-smokers or passive smokers

          -  BMI in the range of 18.5 to 30 kg/m2

          -  Subject has given written informed consent to participate in the trial prior to
             admission to the trial

        Exclusion Criteria:

          -  Blood donation within the last 90 days prior to planned randomization

          -  Any previous medication within 10 days before the planned administration of the
             radiolabelled Investigational Medicinal Product (rIMP) which, in the opinion of the
             physician responsible, will interfere with the study procedures or compromise safety

          -  Subject has any non-removable metal objects such as metal plates, screws etc. in their
             chest or abdominal area which, in the opinion of the physician responsible, could
             affect the study conduct.

          -  Vegetarian

          -  Subjects for whom participation in this study will exceed the limits of total
             radiation exposure allowed in any 12 month period (5 Millisievert), or will exceed 10
             Millisievert over any three year period
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bio-Images Research Ltd</name>
      <address>
        <city>Glasgow</city>
        <state>Glasgow City</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

